Symbols / DRUG
DRUG Chart
About
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 884.52M |
| Enterprise Value | 783.00M | Income | -19.84M | Sales | — |
| Book/sh | 8.37 | Cash/sh | 9.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 26 | IPO | — |
| P/E | — | Forward P/E | -13.63 | PEG | — |
| P/S | — | P/B | 10.64 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 56.59 |
| Current Ratio | 57.37 | Debt/Eq | 0.12 | LT Debt/Eq | — |
| EPS (ttm) | -2.02 | EPS next Y | -6.54 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-15 | ROA | -15.72% |
| ROE | -26.98% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 9.73M |
| Shs Float | 6.63M | Short Float | 7.02% | Short Ratio | 2.06 |
| Short Interest | — | 52W High | 123.75 | 52W Low | 23.18 |
| Beta | -0.49 | Avg Volume | 181.14K | Volume | 93.50K |
| Target Price | $153.52 | Recom | Strong_buy | Prev Close | $86.50 |
| Price | $89.09 | Change | 2.99% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$153.78
Mean price target
2. Current target
$88.36
Latest analyst target
3. DCF / Fair value
$-14.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$88.36
Low
$115.96
High
$191.59
Mean
$153.78
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | BTIG | Buy → Buy | $147 |
| 2026-01-07 | main | BTIG | Buy → Buy | $147 |
| 2026-01-06 | main | BTIG | Buy → Buy | $147 |
| 2026-01-02 | main | Chardan Capital | Buy → Buy | $80 |
| 2025-12-30 | reit | HC Wainwright & Co. | Buy → Buy | $115 |
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-09-08 | init | BTIG | — → Buy | $72 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-05-21 | main | Chardan Capital | Buy → Buy | $80 |
| 2025-05-13 | init | TD Cowen | — → Buy | — |
| 2025-05-07 | init | Chardan Capital | — → Buy | $80 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-01-23 | init | Piper Sandler | — → Overweight | $93 |
| 2025-01-10 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-01-10 | init | HC Wainwright & Co. | — → Buy | $85 |
| 2024-11-25 | init | Baird | — → Outperform | $75 |
- These 4 charts show the scale of Novo Nordisk's woes - CNBC Wed, 25 Feb 2026 10
- Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short - Yahoo Finance Mon, 23 Feb 2026 22
- This Small-Cap Biotech Stock Is Soaring 29%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's ue, 24 Feb 2026 16
- Viking Therapeutics Stock Jumps 11% After Obesity Drug Update: Analysts See $93 Target - TIKR.com ue, 24 Feb 2026 20
- Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short - The Motley Fool Mon, 23 Feb 2026 22
- Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now? - Zacks Investment Research Fri, 20 Feb 2026 15
- Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin - Investor's Business Daily Mon, 23 Feb 2026 21
- Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound - WSJ Mon, 23 Feb 2026 16
- Novo Nordisk’s stock closes at 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial - MarketWatch Mon, 23 Feb 2026 10
- Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip? - Barchart.com Mon, 23 Feb 2026 21
- JPMorgan downgrades Novo Nordisk stock rating on drug trial data - Investing.com ue, 24 Feb 2026 06
- Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why - Investopedia Mon, 23 Feb 2026 16
- Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial - CNBC Mon, 23 Feb 2026 09
- $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges - The Motley Fool Sun, 22 Feb 2026 18
- Why Novo Nordisk Stock Is Plunging—and Why It’s Good News for Eli Lilly - Barron's Mon, 23 Feb 2026 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2400 | 85003 | — | Disposition in the public market at price 35.42 per share. | Pedersen (Jan Torleif) | Director of Issuer | — | 2025-04-02 00:00:00 | D |
| 1 | 5000 | 6425 | — | Exercise of options at price 1.28 per share. | Bottler (Nils Christian) | Director of Issuer | — | 2025-03-24 00:00:00 | D |
| 2 | 16000 | 69504 | — | Exercise of options at price 4.34 per share. | Fryzuk (Jeremy) | Director of Issuer | — | 2025-03-04 00:00:00 | D |
| 3 | 5000 | 180985 | — | Disposition in the public market at price 36.20 per share. | Bottler (Nils Christian) | Director of Issuer | — | 2025-02-28 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.05M | -2.74M | -7.33M | -14.98M |
| TotalUnusualItems | 188.77K | -9.31K | 14.19K | 10.15K |
| TotalUnusualItemsExcludingGoodwill | 188.77K | -9.31K | 14.19K | 10.15K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.23M | -2.80M | -7.37M | -14.96M |
| ReconciledDepreciation | 76.87K | 73.36K | 72.45K | 6.04K |
| EBITDA | -13.86M | -2.75M | -7.31M | -14.97M |
| EBIT | -13.94M | -2.82M | -7.39M | -14.98M |
| NetInterestIncome | 1.52M | 30.13K | 0.00 | 0.00 |
| InterestIncome | 1.52M | 30.13K | 0.00 | 0.00 |
| NormalizedIncome | -12.42M | -2.79M | -7.39M | -14.98M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.23M | -2.80M | -7.37M | -14.96M |
| TotalExpenses | 13.94M | 2.82M | 7.39M | 14.98M |
| DilutedAverageShares | 6.88M | 4.31M | 3.72M | 2.47M |
| BasicAverageShares | 6.88M | 4.31M | 3.72M | 2.47M |
| DilutedEPS | -1.78 | -0.65 | -1.98 | -6.06 |
| BasicEPS | -1.78 | -0.65 | -1.98 | -6.06 |
| DilutedNIAvailtoComStockholders | -12.23M | -2.80M | -7.37M | -14.96M |
| NetIncomeCommonStockholders | -12.23M | -2.80M | -7.37M | -14.96M |
| NetIncome | -12.23M | -2.80M | -7.37M | -14.96M |
| NetIncomeIncludingNoncontrollingInterests | -12.23M | -2.80M | -7.37M | -14.96M |
| NetIncomeContinuousOperations | -12.23M | -2.80M | -7.37M | -14.96M |
| PretaxIncome | -12.23M | -2.80M | -7.37M | -14.96M |
| OtherIncomeExpense | 188.77K | -9.31K | 14.19K | 10.15K |
| OtherNonOperatingIncomeExpenses | -243.08K | -181.74K | ||
| SpecialIncomeCharges | 0.00 | 0.00 | -2.00K | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 2.00K | 0.00 |
| GainOnSaleOfSecurity | 188.77K | -9.31K | 14.19K | 12.15K |
| NetNonOperatingInterestIncomeExpense | 1.52M | 30.13K | 0.00 | 0.00 |
| TotalOtherFinanceCost | 18.66K | |||
| InterestIncomeNonOperating | 1.52M | 30.13K | 0.00 | 0.00 |
| OperatingIncome | -13.94M | -2.82M | -7.39M | -14.98M |
| OperatingExpense | 13.94M | 2.82M | 7.39M | 14.98M |
| OtherOperatingExpenses | 287.65K | 197.19K | 186.65K | 243.08K |
| ResearchAndDevelopment | 11.08M | 1.18M | 5.00M | 12.18M |
| SellingGeneralAndAdministration | 2.57M | 1.45M | 2.20M | 2.55M |
| SellingAndMarketingExpense | 429.66K | 41.60K | 119.42K | 551.86K |
| GeneralAndAdministrativeExpense | 2.14M | 1.40M | 2.08M | 2.00M |
| OtherGandA | 1.64M | 910.18K | 923.88K | 1.90M |
| SalariesAndWages | 497.31K | 493.79K | 1.16M | 99.44K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 7.64M | 4.52M | 3.77M | 3.52M |
| ShareIssued | 7.64M | 4.52M | 3.77M | 3.52M |
| TotalDebt | 125.78K | 118.96K | 73.55K | 139.91K |
| TangibleBookValue | 82.04M | 5.54M | 6.60M | 10.54M |
| InvestedCapital | 82.04M | 5.54M | 6.60M | 10.54M |
| WorkingCapital | 81.97M | 5.46M | 6.53M | 10.48M |
| NetTangibleAssets | 82.04M | 5.54M | 6.60M | 10.54M |
| CapitalLeaseObligations | 125.78K | 118.96K | 73.55K | 139.91K |
| CommonStockEquity | 82.04M | 5.54M | 6.60M | 10.54M |
| TotalCapitalization | 82.04M | 5.54M | 6.60M | 10.54M |
| TotalEquityGrossMinorityInterest | 82.04M | 5.54M | 6.60M | 10.54M |
| StockholdersEquity | 82.04M | 5.54M | 6.60M | 10.54M |
| OtherEquityInterest | 455.57K | 831.83K | -33.68K | |
| GainsLossesNotAffectingRetainedEarnings | 5.37M | 4.01M | 3.40M | 2.48M |
| RetainedEarnings | -46.58M | -34.35M | -31.55M | -24.17M |
| CapitalStock | 123.25M | 35.42M | 33.91M | 32.24M |
| CommonStock | 123.25M | 35.42M | 33.91M | 32.24M |
| TotalLiabilitiesNetMinorityInterest | 2.38M | 568.26K | 280.86K | 1.54M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 41.25K | 39.58K | 0.00 | 71.98K |
| LongTermDebtAndCapitalLeaseObligation | 41.25K | 39.58K | 0.00 | 71.98K |
| LongTermCapitalLeaseObligation | 41.25K | 39.58K | 0.00 | 71.98K |
| CurrentLiabilities | 2.34M | 528.68K | 280.86K | 1.47M |
| CurrentDebtAndCapitalLeaseObligation | 84.53K | 79.38K | 73.55K | 67.93K |
| CurrentCapitalLeaseObligation | 84.53K | 79.38K | 73.55K | 67.93K |
| PayablesAndAccruedExpenses | 2.25M | 449.30K | 207.31K | 1.40M |
| CurrentAccruedExpenses | 540.55K | 41.75K | 25.00K | 158.18K |
| Payables | 1.71M | 407.55K | 182.31K | 1.25M |
| AccountsPayable | 1.71M | 407.55K | 182.31K | 1.25M |
| TotalAssets | 84.42M | 6.10M | 6.88M | 12.09M |
| TotalNonCurrentAssets | 111.97K | 117.66K | 66.41K | 138.86K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 2.00K | ||
| NetPPE | 111.97K | 117.66K | 66.41K | 138.86K |
| GrossPPE | 111.97K | 117.66K | 66.41K | 138.86K |
| Leases | 111.97K | 117.66K | 66.41K | 138.86K |
| OtherProperties | 138.86K | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 84.31M | 5.99M | 6.81M | 11.95M |
| PrepaidAssets | 987.91K | 216.63K | 27.69K | 164.43K |
| Receivables | 413.07K | 50.22K | 36.98K | 155.78K |
| OtherReceivables | 41.26K | |||
| TaxesReceivable | 209.92K | 50.22K | 36.98K | 114.52K |
| AccruedInterestReceivable | 203.15K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 82.91M | 5.72M | 6.75M | 11.63M |
| CashAndCashEquivalents | 82.91M | 5.72M | 6.75M | 11.63M |
| CashEquivalents | 86.25K | 86.25K | 86.25K | 86.25K |
| CashFinancial | 82.82M | 5.63M | 6.66M | 11.54M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -8.69M | -1.85M | -7.02M | -13.59M |
| RepaymentOfDebt | -100.15K | -89.73K | -86.11K | -7.16K |
| IssuanceOfCapitalStock | 82.10M | 900.00K | 1.22M | 4.03M |
| EndCashPosition | 82.91M | 5.72M | 6.75M | 11.63M |
| BeginningCashPosition | 5.72M | 6.75M | 11.63M | 19.76M |
| EffectOfExchangeRateChanges | 312.62K | 11.72K | -45.35K | 258.82K |
| ChangesInCash | 76.88M | -1.04M | -4.83M | -8.39M |
| FinancingCashFlow | 85.57M | 810.57K | 2.19M | 5.20M |
| CashFlowFromContinuingFinancingActivities | 85.57M | 810.57K | 2.19M | 5.20M |
| NetOtherFinancingCharges | -360.14K | -26.98K | -799.98K | -1.81M |
| ProceedsFromStockOptionExercised | 3.93M | 302.00 | 1.09M | 1.97M |
| NetCommonStockIssuance | 82.10M | 900.00K | 1.22M | 4.03M |
| CommonStockIssuance | 82.10M | 900.00K | 1.22M | 4.03M |
| NetIssuancePaymentsOfDebt | -100.15K | -89.73K | -86.11K | -7.16K |
| NetLongTermDebtIssuance | -100.15K | -89.73K | -86.11K | -7.16K |
| LongTermDebtPayments | -100.15K | -89.73K | -86.11K | -7.16K |
| OperatingCashFlow | -8.69M | -1.85M | -7.02M | -13.59M |
| CashFlowFromContinuingOperatingActivities | -8.69M | -1.85M | -7.02M | -13.59M |
| ChangeInWorkingCapital | 554.99K | 39.81K | -941.72K | 724.13K |
| ChangeInOtherCurrentLiabilities | 2.17K | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 1.69M | 241.99K | -1.20M | 765.99K |
| ChangeInPrepaidAssets | -771.28K | -188.94K | 136.74K | 3.78K |
| ChangeInReceivables | -362.85K | -13.24K | 118.80K | -45.63K |
| OtherNonCashItems | 35.85K | 8.95K | 19.75K | 29.42K |
| StockBasedCompensation | 3.18M | 839.77K | 1.15M | 875.06K |
| AssetImpairmentCharge | 0.00 | 0.00 | 2.00K | 0.00 |
| DepreciationAmortizationDepletion | 76.87K | 73.36K | 72.45K | 6.04K |
| DepreciationAndAmortization | 76.87K | 73.36K | 72.45K | 6.04K |
| Depreciation | 76.87K | 73.36K | 72.45K | 6.04K |
| OperatingGainsLosses | -312.69K | -10.13K | 45.35K | -258.82K |
| NetForeignCurrencyExchangeGainLoss | -312.69K | -10.13K | 45.35K | -258.82K |
| NetIncomeFromContinuingOperations | -12.23M | -2.80M | -7.37M | -14.96M |
Public Trades for DRUG
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|